JPRN-UMIN000050063
Completed
未知
Pharmacokinetic study by single intake of the test food (pilot study) - Pharmacokinetic study by single intake of the test food (pilot study)
ConditionsHealthy adults
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Healthy adults
- Sponsor
- Other
- Enrollment
- 25
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Subjects with a serious medical history, or with a history of disorders of the digestive system, circulatory system (e.g., heart failure), endocrine system, etc. Subjects who have been judged to be inappropriate for the study by the principal investigator. 2\) Subjects who have a history of gastrointestinal resection surgery, excluding appendectomy. 3\) Subjects who are currently taking medication or being treated by a physician. 4\) Subjects who must be scheduled to receive medical treatment or medication during the study period. 5\) Subjects who plan to consume health foods or supplements other than the food under study after consent. 6\) Subjects who are unable to consume the test food due to preference or allergy. Subjects who may have allergies related to the test food. 7\) Heavy drinkers of alcohol and heavy smokers. 8\) Subjects who have difficulty in taking blood samples. 9\) Subjects who donated blood over 200mL in the past 4 weeks or over 400mL in the past 12 weeks. 10\) Subjects who currently or will be participating in another clinical research study during the study period. 11\) Subjects who have irregular sleep or eating habits due to night work or insomnia. 12\) Subjects who are engaged in strenuous physical activity. 13\) Subjects judged as unsuitable for the study by the responsible doctor for other reasons.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in AdolescentsType 2 Diabetes MellitusTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-004993-40-Outside-EU/EEAMerck & Co., Inc.35
Active, not recruiting
Phase 1
PK Study in Adolescents and Young Adults Treated with GlucocorticoidsOsteoporosisMedDRA version: 18.1Level: PTClassification code 10031282Term: OsteoporosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Body processes [G] - Bones and nerves physological processes [G11]EUCTR2012-003414-14-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as19
Active, not recruiting
Not Applicable
PK Study in Adolescents with Glucocorticoid-Induced OsteoporosisEUCTR2012-003414-14-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as16
Active, not recruiting
Phase 1
PK Study in Adolescents and Young Adults Treated with GlucocorticoidsEUCTR2012-003414-14-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.24
Active, not recruiting
Phase 1
PK Study in Adolescents and Young Adults Treated with GlucocorticoidsOsteoporosisMedDRA version: 18.1Level: PTClassification code 10031282Term: OsteoporosisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Body processes [G] - Bones and nerves physological processes [G11]EUCTR2012-003414-14-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as19